MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Metastatic Solid Tumor
SMARCA4-Deficient Tumor
Advanced Solid Tumor
Non-small Cell Lung Cancer
Interventions
Drug: LY4050784
First Posted Date
2024-08-20
Last Posted Date
2025-01-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
160
Registration Number
NCT06561685
Locations
🇯🇵

National Cancer Center Hospital East, Kashiwa, Chiba, Japan

🇺🇸

UCLA, Santa Monica, California, United States

🇺🇸

University of Colorado Health Hospital, Aurora, Colorado, United States

and more 18 locations
© Copyright 2025. All Rights Reserved by MedPath